Patterns of response in patients with pretreated metastatic melanoma who received ipilimumab 3 mg/kg in a European expanded access program: five illustrative case reports.

Abstract

Ipilimumab 3 mg/kg was the first agent to improve survival of pretreated advanced melanoma patients. Nonconventional response patterns to ipilimumab have been reported widely, but most of these data were from studies with ipilimumab 10 mg/kg. Here, case reports from five patients treated within an expanded access program (EAP) with ipilimumab at its licensed dose of 3 mg/kg illustrate the efficacy of ipilimumab in an expanded access setting and the range of different tumor response patterns encountered. The durable clinical benefit seen in these patients despite the observed atypical response patterns highlights the necessity for comprehensive clinical decision making.

• Authors: Sofie Wilgenhof, Stephanie Du Four, Hendrik Everaert, Bart Neyns
• Journal: Cancer investigation (Cancer Invest) Vol. 30 Issue 10 Pg. 712-20 (Dec 2012) ISSN: 1532-4192 [Electronic] England
• PMID: 23043499 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antineoplastic Agents
• Ipilimumab

Topics

• Adult
• Aged
• Antibodies, Monoclonal (therapeutic use)
• Antineoplastic Agents (therapeutic use)
• Europe
• Female
• Humans
• Ipilimumab
• Male
• Melanoma (drug therapy, mortality)
• Middle Aged
• Salvage Therapy (methods)
• Skin Neoplasms (drug therapy)
• Treatment Outcome